glutathione synthetase ags cell line - CRL-1739 Extracellular glutathione is unable to

Treatment-resistant depression complicates patient care and increases health care burden.3,8 Although there is no agreed-upon clinical definition for treatment-resistant depression, the working definition is an inadequate response to at least 2 antidepressant trials, with agents of differing classes of adequate dose and duration and treatment adherence.3 Table 1 describes in greater detail a system of staging treatment-resistant depression.9 The primary diagnosis of MDD should be confirmed in patients who appear to have treatment-resistant depression

Screening and follow-up are not optional.

doi: 10.3389/fphar.2023.1196287 Received 29 March 2023 Accepted 02 May 2023 Published 15 May 2023 Volume 14 - 2023 Edited by Daniela Gabbia, University of Padova, Italy Reviewed by Xiao Li, Shandong Provincial Qianfoshan Hospital, China Hartmut Kuhn, Charit University Medicine Berlin, Germany Updates Copyright 2023 Lu, Hu, Chen, Li, Yuan, Tian, Cao and Qiu

Furthermore, LBP supplementation exhibited a noteworthy impact on ameliorating DOX-induced acute cardiotoxicity by increasing the activities of SOD and GSH-Px and reducing myocardial MDA levels [308] (Fig